CN111088283B - mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 - Google Patents
mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 Download PDFInfo
- Publication number
- CN111088283B CN111088283B CN202010203073.6A CN202010203073A CN111088283B CN 111088283 B CN111088283 B CN 111088283B CN 202010203073 A CN202010203073 A CN 202010203073A CN 111088283 B CN111088283 B CN 111088283B
- Authority
- CN
- China
- Prior art keywords
- gene
- virus
- mvsv
- vaccine
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Abstract
Description
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010203073.6A CN111088283B (zh) | 2020-03-20 | 2020-03-20 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
PCT/CN2021/081524 WO2021185310A1 (zh) | 2020-03-20 | 2021-03-18 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010203073.6A CN111088283B (zh) | 2020-03-20 | 2020-03-20 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111088283A CN111088283A (zh) | 2020-05-01 |
CN111088283B true CN111088283B (zh) | 2020-06-23 |
Family
ID=70400536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010203073.6A Active CN111088283B (zh) | 2020-03-20 | 2020-03-20 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111088283B (zh) |
WO (1) | WO2021185310A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10131921B2 (en) | 2008-03-06 | 2018-11-20 | Mayo Foundation For Medical Education And Research | Single cycle replicating adenovirus vectors |
US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
WO2018067546A1 (en) | 2016-10-03 | 2018-04-12 | President And Fellows Of Harvard College | Delivery of therapeutic rnas via arrdc1-mediated microvesicles |
US20210338804A1 (en) * | 2020-02-21 | 2021-11-04 | International Aids Vaccine Initiative Inc. | Vaccine Compositions For Preventing Coronavirus Disease |
CN111088283B (zh) * | 2020-03-20 | 2020-06-23 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
WO2021045836A1 (en) | 2020-04-02 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
CN113599512A (zh) * | 2020-05-04 | 2021-11-05 | 国光生物科技股份有限公司 | 免疫组合物 |
US20240123053A1 (en) * | 2020-05-07 | 2024-04-18 | Bharat Biotech International Limited | Coronavirus vaccine through nasal immunization |
WO2021226520A1 (en) * | 2020-05-08 | 2021-11-11 | Kiromic BioPharma, Inc. | Peptide compositions for the treatment of pathogenic infections |
CN111662379B (zh) * | 2020-05-09 | 2021-03-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 抗新型冠状病毒的抗体、制备方法和应用 |
WO2021232050A1 (en) * | 2020-05-11 | 2021-11-18 | Board Of Regents, The University Of Texas System | Natural killer cell immunotherapy for the treatment or prevention of sars-cov-2 infection |
CN111518175B (zh) * | 2020-05-11 | 2021-02-26 | 广东珩达生物医药科技有限公司 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
WO2021228092A1 (en) * | 2020-05-11 | 2021-11-18 | Chang Gung Memorial Hospital, Linkou | Novel monoclonal antibodies against sars-cov-2 and uses thereof |
CN111467489B (zh) * | 2020-05-12 | 2022-06-03 | 上海荣瑞医药科技有限公司 | 一种治疗肿瘤的药物 |
CN111286493B (zh) * | 2020-05-12 | 2020-10-27 | 上海荣瑞医药科技有限公司 | 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物 |
CN111529701A (zh) * | 2020-05-14 | 2020-08-14 | 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) | 一种口服后产生新型冠状病毒抗体的制剂及其制备方法 |
CN111671890B (zh) * | 2020-05-14 | 2022-08-05 | 苏州大学 | 一种新型冠状病毒疫苗及其应用 |
DE20175031T1 (de) * | 2020-05-15 | 2021-09-09 | Euroimmun Medizinische Labordiagnostika Ag | Verfahren zur Bestimmung der Wirksamkeit eines SARS-CoV-2 Impfstoffs |
CN111518740A (zh) * | 2020-05-18 | 2020-08-11 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达SARS-CoV-2 S基因的重组植物乳酸菌及其制备方法 |
JP2023525936A (ja) * | 2020-05-18 | 2023-06-19 | 康希諾(上海)生物科技有限公司 | mRNA又はmRNA組成物、その調製方法及び使用 |
US11129890B1 (en) * | 2020-05-19 | 2021-09-28 | Vigene Biosciences, Inc. | Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein |
CN113683687B (zh) * | 2020-05-19 | 2023-01-31 | 益科思特(北京)医药科技发展有限公司 | 抗新型冠状病毒Spike蛋白抗体及其应用 |
RU2723008C9 (ru) * | 2020-05-19 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Способ получения штамма клеток яичника китайского хомячка, продуцента рекомбинантного белка RBD вируса SARS-CoV-2, штамм клеток яичника китайского хомячка, продуцент рекомбинантного белка RBD вируса SARS-CoV-2, способ получения рекомбинантного белка RBD вируса SARS-CoV-2, тест-система для иммуноферментного анализа сыворотки или плазмы крови человека и ее применение |
WO2021233989A1 (en) * | 2020-05-20 | 2021-11-25 | Hennrich Alexandru Adrian | Viral vaccine vector for immunization against a betacoronavirus |
WO2021239666A1 (en) * | 2020-05-26 | 2021-12-02 | Diaccurate | Therapeutic methods |
WO2021247567A1 (en) * | 2020-06-01 | 2021-12-09 | Washington University | Coronavirus vaccine constructs and methods of making and using same |
CN113750227A (zh) * | 2020-06-01 | 2021-12-07 | 康希诺生物股份公司 | 一种SARS-CoV-2疫苗 |
CN111647077B (zh) * | 2020-06-02 | 2021-02-09 | 深圳市因诺赛生物科技有限公司 | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 |
US20210395345A1 (en) * | 2020-06-03 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing SARS-CoV-2 Infections and COVID-19 with Anti-SARS-CoV-2 Spike Glycoprotein Antibodies |
CN113278068B (zh) * | 2020-06-04 | 2023-11-10 | 山东宽和正生物医药有限公司 | 针对新冠病毒SARS-CoV-2的单克隆抗体F5 |
WO2021250219A1 (en) * | 2020-06-10 | 2021-12-16 | Bavarian Nordic A/S | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
WO2021254270A1 (zh) * | 2020-06-15 | 2021-12-23 | 上海市公共卫生临床中心 | 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法 |
CN117752779A (zh) * | 2020-06-15 | 2024-03-26 | 睿丰康生物医药科技(浙江)有限公司 | 一种冠状病毒刺突蛋白包膜替换型载体疫苗及其构建方法 |
CN113151184B (zh) * | 2020-06-15 | 2023-03-21 | 上海市公共卫生临床中心 | 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法 |
CN111893097A (zh) * | 2020-06-16 | 2020-11-06 | 惠君生物医药科技(杭州)有限公司 | 一种冠状病毒假病毒包装系统及一步法包装方法 |
CN113797326B (zh) * | 2020-06-17 | 2024-01-19 | 上海君实生物医药科技股份有限公司 | 一种预防冠状病毒引起疾病的疫苗 |
KR20230038205A (ko) * | 2020-06-17 | 2023-03-17 | 메이사 백신즈, 인크. | 키메라 rsv 및 코로나바이러스 단백질, 면역원성 조성물, 및 사용 방법 |
WO2021260176A1 (en) * | 2020-06-25 | 2021-12-30 | Virometix Ag | Synthetic epitopes of betacoronaviruses |
TW202208398A (zh) * | 2020-07-01 | 2022-03-01 | 義大利商萊伊錫拉有限責任公司 | 大猩猩腺病毒核酸及胺基酸序列,包含彼之載體,及其用途 |
WO2022000845A1 (zh) * | 2020-07-01 | 2022-01-06 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种预防SARS-CoV-2的重组蛋白疫苗及其制备方法 |
EP4175667A2 (en) * | 2020-07-03 | 2023-05-10 | Indian Institute of Science | Polypeptide fragments, immunogenic composition against sars-cov-2, and implementations thereof |
WO2022006565A1 (en) * | 2020-07-03 | 2022-01-06 | Kang Zhang | Polypeptides, vaccine compositions, and use thereof for inducing immune response to sars-cov-2 in primates |
RU2733831C1 (ru) * | 2020-07-08 | 2020-10-07 | Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Искусственный ген, кодирующий бицистронную структуру, образованную последовательностями рецептор-связующего домена гликопротеина S коронавируса SARS-CoV-2, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_SC2, обеспечивающая экспрессию искусственного гена и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_SC2, используемого для создания вакцины против коронавируса SARS-CoV-2 |
WO2022011092A1 (en) * | 2020-07-08 | 2022-01-13 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an immune response against sars-cov-2 |
CN111778264B (zh) * | 2020-07-14 | 2021-06-29 | 广州佰芮慷生物科技有限公司 | 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗 |
CN112079906B (zh) * | 2020-07-15 | 2022-11-04 | 张影 | 一种新型冠状病毒刺突蛋白、相关生物材料及其应用、检测试纸和检测试剂盒 |
CN114057848B (zh) * | 2020-08-07 | 2023-11-21 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
US11149286B1 (en) * | 2020-08-17 | 2021-10-19 | Mayo Foundation For Medical Education And Research | Adenovirus vectors and methods for using adenovirus vectors |
US20230338511A1 (en) * | 2020-08-28 | 2023-10-26 | University Of Houston System | Single-chain coronavirus viral membrane protein complexes |
CN112079901B (zh) * | 2020-09-04 | 2021-11-19 | 华中科技大学 | 拮抗多肽及其用于制备抗新型冠状病毒药物的应用 |
EP4212544A1 (en) * | 2020-09-07 | 2023-07-19 | GI Cell, Inc. | Coronavirus-derived receptor binding domain variant with reduced ace2 binding capacity, and vaccine composition comprising same |
US20230331782A1 (en) * | 2020-09-08 | 2023-10-19 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease |
WO2022081707A1 (en) * | 2020-10-13 | 2022-04-21 | The Government Of The United States, As Represented By The Secretary Of The Army | Sars-cov-2 dna vaccine and method of administering thereof |
CN112226413B (zh) * | 2020-10-14 | 2022-04-15 | 苏州大学 | 基于SARS-CoV-2 S蛋白RBD区域的靶向性外泌体及其制备方法 |
CN112618707B (zh) * | 2020-10-15 | 2023-07-04 | 广州达博生物制品有限公司 | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 |
JP2023545827A (ja) * | 2020-10-16 | 2023-10-31 | プレジデント アンド フェローズ オブ ハーバード カレッジ | コロナウイルスを標的にするwwドメイン活性化細胞外ベシクル |
WO2022083768A1 (zh) * | 2020-10-23 | 2022-04-28 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 免疫原性组合物及其应用 |
CN112175913A (zh) * | 2020-10-28 | 2021-01-05 | 中国人民解放军军事科学院军事医学研究院 | SARS-CoV-2减毒株及其在预防新冠肺炎中的应用 |
WO2022092779A1 (ko) * | 2020-10-29 | 2022-05-05 | 에스케이바이오사이언스 주식회사 | 사스-코로나바이러스-2 항원 물질을 포함하는 바이럴 벡터 및 이의 이용 |
CN112626035A (zh) * | 2020-12-03 | 2021-04-09 | 中国科学院微生物研究所 | 一种新冠肺炎疫苗以及疫苗套件 |
WO2022127705A1 (en) * | 2020-12-17 | 2022-06-23 | Versitech Limited | Compositions immunogenic against influenza and sars coronavirus 2, methods of making and using thereof |
CN112375748B (zh) * | 2021-01-11 | 2021-04-09 | 中国科学院动物研究所 | 基于水疱性口炎病毒载体的新型冠状病毒嵌合重组疫苗及其制备方法与应用 |
CN113475463B (zh) * | 2021-02-03 | 2023-02-24 | 湖州市中心医院 | 一种新型冠状病毒致肺损伤动物模型的建立方法及其小鼠模型 |
CN115040644B (zh) * | 2021-04-08 | 2023-03-07 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 新冠肺炎重组狂犬病病毒载体疫苗 |
CN113073106B (zh) * | 2021-06-04 | 2021-09-07 | 北京华芢生物技术有限公司 | 新型冠状病毒b.1.525尼日利亚突变株rbd的基因及其应用 |
CN113186204B (zh) * | 2021-06-11 | 2021-10-15 | 北京华芢生物技术有限公司 | 新型冠状病毒巴西株p.1突变株rbd的基因及其应用 |
CN113621076A (zh) * | 2021-08-31 | 2021-11-09 | 南华大学 | 一种针对新冠病毒变异毒株Delta的融合蛋白、喷鼻式疫苗及其制备方法和应用 |
CN113801208B (zh) * | 2021-09-29 | 2023-09-22 | 中国疾病预防控制中心病毒病预防控制所 | 一种新型冠状病毒的t细胞免疫检测方法 |
WO2023104904A2 (en) * | 2021-12-08 | 2023-06-15 | Genclis | The sars-cov-2 and variants use two independent cell receptors to replicate |
CN114150004B (zh) * | 2022-02-09 | 2022-04-22 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2奥密克戎突变株病毒抗原肽的核酸序列及其应用 |
CN115725657A (zh) * | 2022-09-16 | 2023-03-03 | 中国科学院广州生物医药与健康研究院 | 一种节段化的水泡性口炎病毒载体及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788088A (zh) * | 2003-03-27 | 2006-06-14 | 渥太华健康研究学会 | 突变的水泡性口炎病毒及其用途 |
CN105087645A (zh) * | 2015-08-04 | 2015-11-25 | 上海交通大学 | M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101007168B (zh) * | 2006-01-23 | 2010-06-09 | 北京大学 | 一种sars疫苗及其制备方法 |
CA2916789C (en) * | 2013-06-26 | 2022-07-05 | The University Of Western Ontario | Modified matrix proteins of vesicular stomatitis virus |
CN111088283B (zh) * | 2020-03-20 | 2020-06-23 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
-
2020
- 2020-03-20 CN CN202010203073.6A patent/CN111088283B/zh active Active
-
2021
- 2021-03-18 WO PCT/CN2021/081524 patent/WO2021185310A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788088A (zh) * | 2003-03-27 | 2006-06-14 | 渥太华健康研究学会 | 突变的水泡性口炎病毒及其用途 |
CN105087645A (zh) * | 2015-08-04 | 2015-11-25 | 上海交通大学 | M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用 |
Non-Patent Citations (2)
Title |
---|
Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors;Xinkui Fang et al.;《Vaccine》;20120102;第30卷;第1313-1321页 * |
Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12=GFP Displays Immunogenic and Oncolytic Activity;Anthony N. van den Pol,;《Journal of Virology》;20130131;第87卷(第2期);第1019-1034页 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Also Published As
Publication number | Publication date |
---|---|
WO2021185310A1 (zh) | 2021-09-23 |
CN111088283A (zh) | 2020-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
WO2021254327A1 (zh) | 一种包膜替换型病毒载体疫苗及其构建方法 | |
US11911462B2 (en) | Nucleic acid vaccine against the SARS-CoV-2 coronavirus | |
ES2629860T3 (es) | Vectores virales recombinantes | |
US10227385B2 (en) | Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection | |
US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
AU2018232999A1 (en) | Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD) | |
US20050002953A1 (en) | SARS-coronavirus virus-like particles and methods of use | |
WO2020063370A2 (zh) | 免疫组合物及其制备方法与应用 | |
CN113201507B (zh) | 一种重组的伪狂犬病病毒及其疫苗组合物 | |
CN113151184B (zh) | 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法 | |
CN113666990A (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
Zeshan et al. | Protective immune responses induced by in ovo immunization with recombinant adenoviruses expressing spike (S1) glycoprotein of infectious bronchitis virus fused/co-administered with granulocyte-macrophage colony stimulating factor | |
WO2022071513A1 (ja) | SARS-CoV-2に対する改良型DNAワクチン | |
WO2023138334A1 (zh) | 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用 | |
CA3233697A1 (en) | Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein | |
TW202118771A (zh) | 疫苗 | |
JP2023523423A (ja) | SARS-CoV-2に対するワクチン及びその調製物 | |
Schulze et al. | A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus | |
WO2023023940A1 (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
JP7350864B2 (ja) | 異種スパイクタンパク質を有するh52 ibvワクチン | |
CN113801206A (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
KR101845571B1 (ko) | 전통적 돼지열에 대한 마커 백신 | |
ES2410593T3 (es) | Ácidos nucleicos y polipéptidos de lisavirus quiméricos | |
CN116904489B (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200827 Address after: 311200 4th floor, building 2, ChuanHua Kechuang building, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Patentee after: Huijun biomedical technology (Hangzhou) Co.,Ltd. Address before: Second, 150 teaching building, No. 215000 benevolence Road, Suzhou Industrial Park, Suzhou, Jiangsu Patentee before: SUZHOU ULTRAIMMUNE Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201120 Address after: Office 1201-1, innovation building, 1000 Linjiang East Road, bailongqiao Town, Wucheng District, Jinhua City, Zhejiang Province 321000 Patentee after: Ruifengkang biomedical technology (Zhejiang) Co.,Ltd. Address before: 311200 4th floor, building 2, ChuanHua Kechuang building, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Patentee before: Huijun biomedical technology (Hangzhou) Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: MVSV viral vector and its viral vector vaccine, a vaccine based on mVSV mediated COVID-19 Effective date of registration: 20230926 Granted publication date: 20200623 Pledgee: Yiwu Branch of Industrial Bank Co.,Ltd. Pledgor: Ruifengkang biomedical technology (Zhejiang) Co.,Ltd. Registration number: Y2023980058838 |